Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

NCT05496972 | Active Not Recruiting

• 2 other identifiers: 2020-1063NCI-2021-09908
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.

Conditions

Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Outcome Measures

Primary Outcomes (2)

• Patient satisfaction survey with telemedicine in radiation oncology (RO)

  Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.

  through study completion and average of one year.

• Provider satisfaction survey with telemedicine in radiation oncology (RO)

  Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.

  through study completion and average of one year.

Study Arms (1)

Telemedicine Visits

Participants are asked to fill out a survey about their experience.

Behavioral: Survey Administration

Interventions

Survey Administration BEHAVIORAL

Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine

Telemedicine Visits

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

MD Anderson Cancer Center

You may qualify if:

• Patients will be eligible if they are aged 18 or older and have undergone at least 1 telemedicine encounter (video visit) with the radiation oncology department at MD Anderson or its affiliates within 2 months from the initiation of the study (and prospectively as the study enrolls). This would include weekly see visits, follow-up visits, or consultations
• English speaking
• Access to email and internet to complete the survey
• Attending physicians in the radiation oncology department who have utilized telemedicine will be contacted to fill out surveys reflecting their experience

You may not qualify if:

• Protected populations such as adults unable to consent, pregnant women, prisoners, and individuals who are not yet adults will be excluded

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

• MD Anderson Cancer Center

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Chenyang Wang, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 8, 2022
• First Posted: August 11, 2022
• Study Start: April 21, 2021
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: May 22, 2026

Record last verified: 2026-05

Locations

US (1)